NCT04871997View on ClinicalTrials.gov

A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC)

CompletedOBSERVATIONAL
Enrollment

373

Participants

Timeline

Start Date

July 12, 2019

Primary Completion Date

July 16, 2022

Study Completion Date

July 16, 2022

Conditions
NSCLC
Trial Locations (1)

430030

Hubei province, Wuhan

All Listed Sponsors
lead

Qian Chu

OTHER

NCT04871997 - A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC) | Biotech Hunter | Biotech Hunter